Streetbeat News

Acquisitions Mergers

PLBY

PLBY Group has announced an equity investment by Byborg Enterprises SA, which will purchase 14.9 million shares of PLBY at $1.50 per share. Additionally, Byborg has signed a non-binding letter of intent to license digital IP and operate select Playboy digital assets, committing to $300 million in minimum guaranteed payments over a 15-year term.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:32 pm

DTI

Drilling Tools International Corp. (NASDAQ:DTI) has signed a definitive agreement to acquire UK-based Titan Tools Services Ltd., enhancing its product offerings and expanding its presence in the North Sea, European, and African markets. The acquisition leverages Titan's customer relationships and expertise.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:27 pm

K

Kellanova has announced that it will not be providing guidance due to its pending merger with Mars. This decision may impact investor expectations and stock performance in the short term.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:14 pm

WSR

MCB Real Estate has proposed an all-cash offer of $15.00 per share to Whitestone, which represents a 14.5% premium for shareholders. However, Whitestone's board has rejected the proposal and refused to engage with MCB.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:57 am

NOTE

FiscalNote has announced the divestiture of its South Korean subsidiary, Aicel Technologies, to a group including Aicel's current CEO, lead executive, and a third-party institutional equity investor for $9.65 million. The deal includes $8.5 million in cash and the assumption of an existing convertible note.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:53 am

EQ

Equillium announced that Ono Pharmaceutical has decided not to exercise its option to acquire rights to itolizumab. Equillium is now considering accelerating the completion of its Phase 3 EQUATOR study in aGVHD to Q1 2025, with Phase 2 ulcerative colitis study topline data expected in the same quarter.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:45 am

ALRN

Aileron Therapeutics has entered an exclusive option agreement with Advancium Health Network for the potential acquisition of ALRN-6924, a drug developed by Aileron. Advancium paid a non-refundable fee for the option and plans to evaluate ALRN-6924 as a treatment for retinoblastoma, a rare eye cancer. If the option is exercised, Aileron could receive additional payments and royalties.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:38 am

AVTE

Aerovate Therapeutics and Jade Biosciences have agreed to merge in an all-stock transaction, creating a company focused on Jade's biologics portfolio, including JADE-001 for IgA Nephropathy. The new entity will trade on Nasdaq under 'JBIO'.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:23 am

ADTX

Appili Therapeutics has announced an agreement with the FDA on the development requirements for its ATI-1801 topical antiparasitic product NDA submission. Additionally, Appili has agreed to be acquired by Aditxt, which will acquire all issued and outstanding shares.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:21 am

AME

AMETEK has acquired Virtek Vision, a Canadian company specializing in laser-based projection and inspection systems. Virtek will become part of AMETEK's Electronic Instruments Group. The financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:15 am